Exact Sciences Corporation - Common Stock (NQ:EXAS)

Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting...

Topics Earnings

Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness

January 22, 2026

Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat

Topics Economy

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an...

Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits ↗

Topics Earnings Economy

November 20, 2025

Via Stocktwits

Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover ↗

November 20, 2025

Via Stocktwits

$5.1 Trillion Global Surge: CEO Confidence Ignites New Era of M&A Transformation

January 19, 2026

The global Mergers and Acquisitions (M&A) market staged a historic comeback in 2025, with total deal value reaching a staggering $5.1 trillion. This resurgence represents a 44% year-over-year increase,...

The Great Diagnostic Consolidation: How a $25.7 Billion Mega-Deal Ignited a 150% Surge in Healthcare M&A

Topics Artificial Intelligence Economy Initial Public Offering

January 14, 2026

As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial...

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

Topics Artificial Intelligence

January 13, 2026

In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an...

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that...

On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025...

Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability

January 12, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Topics Artificial Intelligence Death

3 Mid-Cap Stocks We Steer Clear Of

January 08, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

1 High-Flying Stock on Our Watchlist and 2 We Question

January 04, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

3 Unpopular Stocks We Steer Clear Of

December 30, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have realized strong financial performance, and over the past six months, the...

1 Healthcare Stock for Long-Term Investors and 2 We Avoid

December 10, 2025

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...

Topics Stocks

3 Overrated Stocks That Concern Us

December 03, 2025

A combination of operational improvements and developments at its key rival bolstered the stock recently.

Here's Why Grail Soared, Again, in November ↗

December 02, 2025

The healthcare leader wants to make waves in a potentially highly lucrative market.

This Top Dividend King Just Became an Even Better Buy ↗

November 30, 2025

Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Unusual volume stocks are being observed in Monday's session. ↗

November 24, 2025

Via Chartmill

Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks

November 23, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers.

On a big day for tech stocks, some other less well-known companies saw even larger moves.

Topics Artificial Intelligence

Biggest Stock Movers Today, Nov. 20: PACS, BBWI, & More ↗

November 20, 2025

The company received a buyout offer from Abbot Labs.

Topics Artificial Intelligence Stocks

Why Exact Sciences Rallied Over 50% This Week ↗

November 20, 2025

A healthcare giant covets the cancer screening leader's technology.

Why Exact Sciences Stock Surged Today ↗

November 20, 2025

Tech Stocks Fall Despite Nvidia's Beat, Walmart Jumps 6%: What's Moving Markets Thursday? ↗

November 20, 2025

Nvidia Corp. (NASDAQ:NVDA) delivered another blockbuster quarter and raised its outlook, but even that wasn't enough to lift Wall Street on Thursday.

Via Benzinga

Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday ↗

November 20, 2025

Via Benzinga

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics ↗

November 20, 2025

Abbott will acquire Exact Sciences for $21 billion, adding Cologuard and expanding its diagnostics portfolio as analysts highlight growth and valuation momentum.

Via Benzinga

Abbott To Acquire Exact Sciences For Up To $23B ↗

November 20, 2025

Under the deal, Exact Sciences shareholders will receive $105 per common share in cash.

Via Stocktwits

Why Exact Sciences Stock Blasted Nearly 24% Higher Today ↗

November 19, 2025

A strategic investor is reportedly in advanced talks to purchase the company.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

2 Surging Stocks with Competitive Advantages and 1 We Question

November 16, 2025

Exact Sciences’ third quarter results received a positive response from the market, reflecting strong revenue growth and robust execution in its core screening business. Management attributed the...

The 5 Most Interesting Analyst Questions From Exact Sciences’s Q3 Earnings Call

November 10, 2025